FDA Informs Mannkind It Needs More Time to Review AFREZZA NDA

The FDA informed MannKind Corporation that it would not be able to complete the review of the New Drug Application (NDA) for AFREZZA (insulin human [rDNA origin]) Inhalation Powder by the action date of December 29, 2010. The FDA stated that it will require approximately four additional weeks to complete its review of the NDA.

AFREZZA is a novel, ultra rapid acting mealtime insulin therapy being developed by MannKind Corporation for the treatment of adult patients with type 1 and type 2 diabetes. It is a combination product, consisting of AFREZZA Inhalation Powder pre-metered into single use dose cartridges and delivered via a small, discreet and easy-to-use AFREZZA Inhaler.

ASweetLife Team

Are CGMs a Waste of Time for People Without Diabetes? Some experts suggest CGMs are useless for nondiabetics. I disagree. As some of you may already know, I’m a proponent of continuous glucose monitors, or CGMs, in my patients, even…
Gary Taubes' Case for the Keto Diet: A Book Review “We believe than an injustice is being perpetrated that has to be righted.” Gary Taubes doesn’t mince words in his new book, The Case for Keto. The text is his…
New US Dietary Guidelines: More Controversial than Ever It’s that time again: the United States Department of Agriculture will soon issue its new dietary guidelines, as it does every five years. These guidelines are controversial in the best…
Beyond BMI: How to More Accurately Assess Metabolic Health Body Mass Index (BMI) is the standard metric for determining if someone is a healthy weight. BMI is calculated as weight in kilograms divided height in meters squared, and specific…
FDA Approves Tandem’s t:slim X2 Insulin Pump with… The U.S. FDA has announced clearance of an expanded pediatric indication for the Tandem’s t:slim X2™ insulin pump with Control-IQ™ technology to children age 6 and older. The product was previously approved for ages 14…